Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers

Aim:Hematoporphyrin monomethyl ether (HMME), which consists of equal amounts of isomers HMME-1 and HMME-2, is a novel porphyrin-related drug for photodynamic therapy. This study was aimed to investigate the uptake transporter-mediated selective uptake of HMME into the liver and to identify the major uptake transporter isoforms involved.Methods:Adult SD rats were intravenously injected with a single dose of HMME (5 mg/kg) with or without rifampicin (an inhibitor of organic anion transporting polypeptides OATP1B1 and OATP1B3, 25 mg/kg). Blood samples were collected, and HMME concentrations were measured using LC-MS/MS. Rat hepatocytes, human hepatocytes and HEK293 cells expressing OATP1B1, OATP1B3, or OATP2B1 were used to investigate the uptake of HMME or individual isomers in vitro.Results:Co-administration of rifampicin significantly increased the exposure of HMME isomers, and decreased the AUC ratio of HMME-1 to HMME-2 from 1.98 to 1.56. The uptake of HMME-2 into human hepatocytes and the HEK293 cells expressing OATP1B1 or OATP2B1 in vitro was 2–7 times greater than that of HMME-1, whereas OATP1B3 mediated a higher HMME-1 uptake. OATP1B1 exhibited a higher affinity for HMME-2 than for HMME-1 (the Km values were 0.63 and 5.61 μmol/L, respectively), which were similar to those in human hepatocytes. By using telmisartan (a non-specific OATP inhibitor) and rifampicin, OATP2B1 was demonstrated to account for <20% of hepatic HMME uptake.Conclusion:OATP1B1 is the major transporter involved in the rapid hepatic uptake of HMME, and the greater uptake of HMME-2 by OATP1B1 may lead to a lower exposure of HMME-2 than HMME-1 in humans.

[1]  L. Benet,et al.  Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite , 2009, Clinical pharmacology and therapeutics.

[2]  D. Keppler,et al.  Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6* , 2001, The Journal of Biological Chemistry.

[3]  Xia Zhao,et al.  Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers , 2011, Acta Pharmacologica Sinica.

[4]  J. Schuetz,et al.  The role of transporters in cellular heme and porphyrin homeostasis. , 2007, Pharmacology & therapeutics.

[5]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[6]  S. Bates,et al.  ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy , 2005, Cancer biology & therapy.

[7]  C. Funk,et al.  Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3 , 2007, Drug Metabolism and Disposition.

[8]  H. Cai,et al.  Effect of hematoporphyrin monomethyl ether‐mediated photodynamic therapy on hypertrophic scar fibroblasts , 2011, Photodermatology, photoimmunology & photomedicine.

[9]  B. Stieger,et al.  Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil , 2007, Drug Metabolism and Disposition.

[10]  S. Khoo,et al.  HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms , 2010, Pharmacogenetics and genomics.

[11]  D. Keppler,et al.  Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis , 2005, Hepatology.

[12]  T. Ishikawa,et al.  Functional Validation of the Genetic Polymorphisms of Human ATP-Binding Cassette (ABC) Transporter ABCG2: Identification of Alleles That Are Defective in Porphyrin Transport , 2006, Molecular Pharmacology.

[13]  T. Nakanishi,et al.  Functional pleiotropy of organic anion transporting polypeptide OATP2B1 due to multiple binding sites. , 2012, Drug metabolism and pharmacokinetics.

[14]  R. Kim,et al.  Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[15]  A. Enomoto,et al.  Interactions of Human Organic Anion Transporters and Human Organic Cation Transporters with Nonsteroidal Anti-Inflammatory Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[16]  Yuichi Sugiyama,et al.  Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.

[17]  C. Vulpe,et al.  Identification of an Intestinal Heme Transporter , 2005, Cell.

[18]  Y. Sugiyama,et al.  Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. , 1993, The American journal of physiology.

[19]  J. Xu,et al.  Interaction of porphyrins with human organic anion transporting polypeptide 1B1. , 2009, Chemico-biological interactions.

[20]  Kaoru Kobayashi,et al.  Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells , 2005, Pharmacogenetics and genomics.

[21]  Yu-Han Pu,et al.  Research progress of Hemoporfin--part one: preclinical study. , 2012, Photodiagnosis and photodynamic therapy.

[22]  K. Maeda,et al.  Contribution of OATP 2 ( OATP 1 B 1 ) and OATP 8 ( OATP 1 B 3 ) to the Hepatic Uptake of Pitavastatin in Humans , 2004 .

[23]  J. Stangier,et al.  Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patients , 2000, The Journal of international medical research.

[24]  R. Kim,et al.  Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.

[25]  U. Hofmann,et al.  Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). , 2005, British journal of clinical pharmacology.

[26]  M. Clozel,et al.  Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction between Bosentan and Cyclosporin A in the Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.

[27]  H. Koepsell,et al.  Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. , 2009, American journal of physiology. Renal physiology.

[28]  K. Maeda,et al.  Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[29]  K. Maeda,et al.  DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 , 2006, Drug Metabolism and Disposition.

[30]  Kazuya Maeda,et al.  PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS , 2006, Drug Metabolism and Disposition.

[31]  Xiaoyan Chen,et al.  Mechanistic Studies on the Absorption and Disposition of Scutellarin in Humans: Selective OATP2B1-Mediated Hepatic Uptake Is a Likely Key Determinant for Its Unique Pharmacokinetic Characteristics , 2012, Drug Metabolism and Disposition.

[32]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[33]  Li Li,et al.  Intraperitoneal photodynamic therapy for an ovarian cancer ascite model in Fischer 344 rat using hematoporphyrin monomethyl ether , 2007, Cancer science.

[34]  L. Kemény,et al.  Specific inhibition of the ABCG2 transporter could improve the efficacy of photodynamic therapy. , 2011, Journal of photochemistry and photobiology. B, Biology.

[35]  G. Suarez-Kurtz,et al.  The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. , 2010, British journal of clinical pharmacology.

[36]  Yuichi Sugiyama,et al.  Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[37]  S. Vavricka,et al.  Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver , 2002, Hepatology.